NCT00796328

Brief Summary

This study is designed to determine the ED90 for an infusion of phenylephrine to prevent spinal induced low blood pressure in parturients presenting for an elective cesarean delivery. The up-down methodology (UDM) is commonly used study method to determine the dose of a drug that causes the desired effect in over 90% of the subjects to whom it given. For example: the investigators want to know what is the best dose of phenylephrine (from a range of commonly used doses) to prevent a drop in blood pressure during cesarean delivery ninety times out of one hundred when it is given at that dose. The ED90 is the effective dose at which 90% of subjects will have a "positive" response to a phenylephrine infusion, i.e. no drop in blood pressure. The investigators hypothesize that the ED90 will be between 40 - 60 mcg/min. The primary outcome measure is the ED90 for phenylephrine infusions that prevents a drop in blood pressure in women undergoing cesarean delivery.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Nov 2008

Shorter than P25 for phase_4

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2008

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

November 19, 2008

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 24, 2008

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2009

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2009

Completed
4.8 years until next milestone

Results Posted

Study results publicly available

April 21, 2014

Completed
Last Updated

April 23, 2018

Status Verified

March 1, 2018

Enrollment Period

3 months

First QC Date

November 19, 2008

Results QC Date

March 14, 2014

Last Update Submit

March 22, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Effective Dose of Phenylephrine at Which 90% of Subjects Have no Spinal Induced Hypotension

    The effective dose at which 90% of subjects will have a "positive" response to a phenylephrine infusion, i.e. no spinal induced hypotension. We hypothesize that the ED90 will be between 40 - 60 mcg/min.

    Spinal administration until delivery

Study Arms (1)

1

EXPERIMENTAL
Drug: Phenylephrine infusion

Interventions

Up-down, biased coin design

1

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Non-emergent cesarean delivery with planned spinal anesthesia (i.e. elective planned cesarean delivery for malposition, patient choice, cervical pelvic disproportion, previous cesarean delivery and other diagnosis that require a predetermined cesarean delivery)
  • American Society of Anesthesia physical status class I \& II (ASA I - Healthy, ASA II - mild and controlled systemic disease, eg. controlled essential hypertension)
  • Age ≥ 18 years (Standard within the obstetrical literature)
  • Term gestational age
  • English-speaking

You may not qualify if:

  • Morbid Obesity (Body Mass Index ≥ 45 kg/m2) (Morbidly obese parturients require a dose of local anesthetic less than the standardized dose in this study, typically have an exaggerated response to vasopressors, and the blood pressure cuff occasionally needs to be replaced by an intra-arterial catheter due to limitations in size)
  • Height \< 5'0" (Women \< 5'0" are likely to require a dose of local anesthetic less than the standardized dose in this study)
  • Laboring women
  • Urgent or emergency cesarean delivery
  • Hypertensive disease of pregnancy
  • Severe maternal cardiac disease
  • Subjects on monoamine oxidase inhibitors (MAOI's) or tricyclic antidepressants
  • Fetal anomalies or intrauterine fetal death
  • Failed spinal anesthesia
  • Subject enrollment in another study involving a study medication within 30 days of CD
  • Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Results Point of Contact

Title
Dr. Ron George
Organization
IWK Health Centre

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Primary Investigator, MD, FRCPC, Assistant Professor

Study Record Dates

First Submitted

November 19, 2008

First Posted

November 24, 2008

Study Start

November 1, 2008

Primary Completion

February 1, 2009

Study Completion

July 1, 2009

Last Updated

April 23, 2018

Results First Posted

April 21, 2014

Record last verified: 2018-03